A Study of RC108-ADC in Subjects With Advanced Malignant Solid Tumors
This study will evaluate the safety, pharmacokinetics, and effect of RC108-ADC for injeciton in subjects with c-Met positive advanced malignant solid tumors.
Solid Tumor
DRUG: RC108
Number of participants with adverse events, Adverse events was assessed by investigator(s) according to NCI-CTCAE v4.03, From the day of ICF signment to 28 days after the day of the last treatment|Maximum Tolerated dose of RC108, The dose level in which \>= 2 out of 6 patients have dose-limiting toxicity (DLT). The MTD is defined as the previous dose level., 21 days after first treatment.
Objective Response Rate (ORR), Objective Response Rate was defined as the percentage of participants with a complete response (CR) or partial response (PR), 24 months|Progression Free Survival (PFS), Progression-free Survival (PFS) (median) was determined using the number of months measured from the initial date of treatment to the date of documented progression, or the date of death (in the absence of progression) of participants. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions., 24 months|Pharmacokinetics (PK) parameter for total antibody (TAb): Maximum concentration (Cmax), Cmax will be derived from the PK blood samples collected., Dose 1 and Dose 3: pre-dose, 0.5 hour, 1 hour, 1.5 hours, 10 hours, 24 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 336 hours and 504 hours after start of infusion. Dose 2: pre-dose.|PK parameter for TAb: Time to maximum concentration (Tmax), Tmax will be derived from the PK blood samples collected., Dose 1 and Dose 3: pre-dose, 0.5 hour, 1 hour, 1.5 hours, 10 hours, 24 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 336 hours and 504 hours after start of infusion. Dose 2: pre-dose.|PK parameter for TAb: Area under the concentration-time curve (AUC), AUC will be derived from the PK blood samples collected., Dose 1 and Dose 3: pre-dose, 0.5 hour, 1 hour, 1.5 hours, 10 hours, 24 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 336 hours and 504 hours after start of infusion. Dose 2: pre-dose.|PK parameter for TAb: Trough concentration (Ctrough), Ctrough will be derived from the PK blood samples collected., Dose 1 and Dose 3: pre-dose, 0.5 hour, 1 hour, 1.5 hours, 10 hours, 24 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 336 hours and 504 hours after start of infusion. Dose 2: pre-dose.|PK parameter for TAb: Terminal or apparent terminal half-life (t1/2), t1/2 will be derived from the PK blood samples collected., Dose 1 and Dose 3: pre-dose, 0.5 hour, 1 hour, 1.5 hours, 10 hours, 24 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 336 hours and 504 hours after start of infusion. Dose 2: pre-dose.|PK parameter for TAb: Systemic clearance (CL), CL will be derived from the PK blood samples collected., Dose 1 and Dose 3: pre-dose, 0.5 hour, 1 hour, 1.5 hours, 10 hours, 24 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 336 hours and 504 hours after start of infusion. Dose 2: pre-dose.|PK parameter for antibody-drug conjugate (ADC): Cmax, Cmax will be derived from the PK blood samples collected., Dose 1 and Dose 3: pre-dose, 0.5 hour, 1 hour, 1.5 hours, 10 hours, 24 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 336 hours and 504 hours after start of infusion. Dose 2: pre-dose.|PK parameter for ADC: Tmax, Tmax will be derived from the PK blood samples collected., Dose 1 and Dose 3: pre-dose, 0.5 hour, 1 hour, 1.5 hours, 10 hours, 24 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 336 hours and 504 hours after start of infusion. Dose 2: pre-dose.|PK parameter for ADC: AUC, AUC will be derived from the PK blood samples collected., Dose 1 and Dose 3: pre-dose, 0.5 hour, 1 hour, 1.5 hours, 10 hours, 24 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 336 hours and 504 hours after start of infusion. Dose 2: pre-dose.|PK parameter for ADC: Ctrough, Ctrough will be derived from the PK blood samples collected., Dose 1 and Dose 3: pre-dose, 0.5 hour, 1 hour, 1.5 hours, 10 hours, 24 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 336 hours and 504 hours after start of infusion. Dose 2: pre-dose.|PK parameter for ADC: t1/2, t1/2 will be derived from the PK blood samples collected., Dose 1 and Dose 3: pre-dose, 0.5 hour, 1 hour, 1.5 hours, 10 hours, 24 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 336 hours and 504 hours after start of infusion. Dose 2: pre-dose.|PK parameter for ADC: CL, CL will be derived from the PK blood samples collected., Dose 1 and Dose 3: pre-dose, 0.5 hour, 1 hour, 1.5 hours, 10 hours, 24 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 336 hours and 504 hours after start of infusion. Dose 2: pre-dose.|PK parameter for Monomethyl Auristatin E (MMAE): Cmax, Cmax will be derived from the PK blood samples collected., Dose 1 and Dose 3: pre-dose, 0.5 hour, 1 hour, 1.5 hours, 10 hours, 24 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 336 hours and 504 hours after start of infusion. Dose 2: pre-dose.|PK parameter for MMAE: Tmax, Tmax will be derived from the PK blood samples collected., Dose 1 and Dose 3: pre-dose, 0.5 hour, 1 hour, 1.5 hours, 10 hours, 24 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 336 hours and 504 hours after start of infusion. Dose 2: pre-dose.|PK parameter for MMAE: AUC, AUC will be derived from the PK blood samples collected., Dose 1 and Dose 3: pre-dose, 0.5 hour, 1 hour, 1.5 hours, 10 hours, 24 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 336 hours and 504 hours after start of infusion. Dose 2: pre-dose.|PK parameter for MMAE: Ctrough, Ctrough will be derived from the PK blood samples collected., Dose 1 and Dose 3: pre-dose, 0.5 hour, 1 hour, 1.5 hours, 10 hours, 24 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 336 hours and 504 hours after start of infusion. Dose 2: pre-dose.|PK parameter for MMAE: t1/2, t1/2 will be derived from the PK blood samples collected., Dose 1 and Dose 3: pre-dose, 0.5 hour, 1 hour, 1.5 hours, 10 hours, 24 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 336 hours and 504 hours after start of infusion. Dose 2: pre-dose.|PK parameter for MMAE: CL, CL will be derived from the PK blood samples collected., Dose 1 and Dose 3: pre-dose, 0.5 hour, 1 hour, 1.5 hours, 10 hours, 24 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 336 hours and 504 hours after start of infusion. Dose 2: pre-dose.|Immunogenicity assessment, Assessment of anti-RC108 antibodies, Dose 1 to Dose 3: pre-dose, and 504 hours after start of infusion (Dose 3 only)
This study will evaluate the safety, pharmacokinetics, and effect of RC108-ADC for injeciton in subjects with c-Met positive advanced malignant solid tumors.